Loading…
Pyxis Oncology, Inc. is projected to rise to $3.09 by 2027, a +17% move from its current price of $2.65. PYXS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.49 | $2.65 | $2.82 | +0.11% |
| Aug 5 | $2.43 | $2.66 | $2.90 | +0.22% |
| Aug 6 | $2.39 | $2.66 | $2.96 | +0.33% |
| Aug 7 | $2.35 | $2.66 | $3.01 | +0.44% |
| Aug 8 | $2.32 | $2.66 | $3.06 | +0.55% |
| Aug 9 | $2.29 | $2.67 | $3.10 | +0.66% |
| Aug 10 | $2.27 | $2.67 | $3.14 | +0.77% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.27 | $2.67 | $3.14 | +0.77% |
| Week 2 | $2.14 | $2.69 | $3.39 | +1.55% |
| Week 3 | $2.05 | $2.71 | $3.59 | +2.33% |
| Week 4 | $1.97 | $2.73 | $3.78 | +3.12% |
| Week 5 | $1.91 | $2.75 | $3.96 | +3.92% |
| Week 6 | $1.86 | $2.78 | $4.13 | +4.72% |
| Week 7 | $1.82 | $2.80 | $4.30 | +5.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pyxis Oncology, Inc. is a healthcare company at the clinical stage that develops therapeutics to treat solid tumors. Its lead antibody-drug conjugate PYX-201 is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors.
The company also advances PYX-102, an investigational immunotherapeutic targeting KLRG1, with potential for use as monotherapy or in combination treatments, and PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody in Phase 1 to treat advanced solid tumors.
Pyxis Oncology is expanding its portfolio with PYX-107, a CD40 agonist that has demonstrated anti-cancer activity and is in Phase 2 to treat tumors including soft tissue sarcomas, esophageal cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, among others, and Biosion USA, Inc.
to develop PYX-106. Pyxis Oncology was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Pyxis Oncology, Inc. trades under the symbol PYXS and has a current price of $2.65 with a market cap of $167.89M, ranking 3868 by market capitalization.
The 30-day forecast presents a path of evolving value with an average forecast price of $2.65 in 2026, a min of $1.15 and a max of $4.00, and an ROI of 0 with a NEUTRAL sentiment for that year. The multi-year forecast shows meaningful upside: by 2030 the average is $7.11 with a max of $12.31 and an ROI of 168.1% (BULLISH); by 2040 the average is $20.46 with a max of $44.86 and an ROI of 672% (BULLISH); and by 2050 the average is $67.22 with a max of $154.61 and an ROI of 2436.6% (BULLISH). These figures illustrate a potential long-term upside given the company’s oncology pipeline and licensing partnerships.
A major floor 52.1% below — a decisive break under it would weaken the trend.
The nearest floor, 23.4% below — buyers have tended to step in here.
The nearest ceiling, 15.8% above — a clean break opens room to run.
A major ceiling 36.7% above — clearing it would confirm fresh momentum.
Key PYXS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PYXS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.85 | Sell | $2.76 | Sell |
| MA 10 | $2.66 | Sell | $2.70 | Sell |
| MA 20 | $2.59 | Buy | $2.60 | Buy |
| MA 50 | $2.24 | Buy | $2.36 | Buy |
| MA 100 | $2.00 | Buy | $2.18 | Buy |
| MA 200 | $2.34 | Buy | $2.12 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.28 | Neutral |
| Stoch RSI (14) | 42.27 | Neutral |
| CCI (20) | 18.34 | Neutral |
| Williams %R (14) | -39.13 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 9.05 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 60.87 | Neutral |
| TRIX (15) | 0.77 | Buy |
| Awesome (5,34) | 0.39 | Buy |
| Ultimate (7,14,28) | 56.71 | Neutral |
| Momentum (10) | 0.29 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 2.92 | Sell |
| ADX (14) | 16.48 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is BULLISH in sentiment.
RSI(14) is 50, with the 50-day simple moving average at $2.24 and the 200-day simple moving average at $2.34. Support is identified at $2.03 and resistance at $3.07. Over the past 30 days, the price has traded in a range from $1.77 to $3.97, indicating a broad near-term trading channel.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.15 | $2.65 | $3.99 | 0% | Neutral | |
| $2.25 | $3.09 | $4.58 | +17% | Neutral | |
| $2.55 | $3.73 | $5.90 | +41% | Bullish | |
| $2.94 | $4.53 | $7.53 | +71% | Bullish | |
| $4.39 | $7.09 | $12.27 | +167% | Bullish | |
| $5.64 | $9.51 | $17.05 | +259% | Bullish | |
| $4.95 | $8.70 | $16.09 | +228% | Bullish | |
| $5.39 | $9.87 | $18.75 | +272% | Bullish | |
| $6.01 | $11.44 | $22.31 | +332% | Bullish | |
| $5.24 | $10.38 | $20.70 | +292% | Bullish | |
| $9.22 | $20.49 | $44.94 | +673% | Bullish | |
| $30.24 | $67.19 | $154.54 | +24.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.15 | $2.65 | $3.18 | +0.00% |
| September 2026 | $2.17 | $2.64 | $3.35 | -0.39% |
| October 2026 | $2.38 | $2.93 | $3.79 | +10.97% |
| November 2026 | $2.44 | $3.04 | $4.00 | +3.90% |
| December 2026 | $2.37 | $2.99 | $3.99 | -1.70% |
Click any year to see its month-by-month PYXS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PYXS could reach as high as $3.99, with a base case around $2.65 and support toward $1.15 — roughly 0% from $2.65. A consolidation phase looks the most probable path here.
Expect PYXS to range from $2.25 to $4.58 through 2027. The $3.09 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
The PYXS price prediction for 2028 points to an average of $3.73 (low $2.55, high $5.90) — a potential gain of +41% on today's $2.65. Buyers look set to stay in control over this stretch.
In 2029, PYXS is projected to trade between $2.94 and $7.53, averaging $4.53 — a potential gain of +71% from today's $2.65. That is up +22% on the projected 2028 average. Momentum favours further upside here.
Pyxis Oncology, Inc.'s 2030 outlook centres on $7.09, within a $4.39 to $12.27 range. That is up +56% on the projected 2029 average. That marks a +167% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, PYXS could reach as high as $17.05, with a base case around $9.51 and support toward $5.64 — roughly +259% from $2.65. Momentum favours further upside here.
Expect PYXS to range from $4.95 to $16.09 through 2032. The $8.70 average target implies a +228% move from current prices. That is -8% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The PYXS price prediction for 2033 points to an average of $9.87 (low $5.39, high $18.75) — a potential gain of +272% on today's $2.65. Momentum favours further upside here.
In 2034, PYXS is projected to trade between $6.01 and $22.31, averaging $11.44 — a potential gain of +332% from today's $2.65. That is up +16% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Pyxis Oncology, Inc.'s 2035 outlook centres on $10.38, within a $5.24 to $20.70 range. That is -9% versus the projected 2034 average. That marks a +292% change versus current levels. Momentum favours further upside here.
By 2040, PYXS could reach as high as $44.94, with a base case around $20.49 and support toward $9.22 — roughly +673% from $2.65. Buyers look set to stay in control over this stretch.
Expect PYXS to range from $30.24 to $154.54 through 2050. The $67.19 average target implies a +24.4x move from current prices. That is up +228% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PYXS today (≈ 377.358491 PYXS) could be worth
$25,354.72
+$24,354.72 (+2435%) by 2050 · US Dollar
Based on the average projected PYXS price of $67.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PYXSwould be worth at today's price.
$1,000 invested in PYXS on Jul 31, 2025 (≈ 892.857139 PYXS) would be worth
$2,366.07
+$1,366.07 (+136.6%) today · 2.37× · US Dollar
Based on a PYXS entry price of $1.12 vs. today's $2.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.61 | $1,015.33 | +1.5% |
| 1 month ago | $2.85 | $929.82 | -7.0% |
| 3 months ago | $1.72 | $1,540.7 | +54.1% |
| 6 months ago | $1.53 | $1,732.03 | +73.2% |
| 1 year ago | $1.12 | $2,366.07 | +136.6% |
| All time (4.8y) ago | $13.2 | $200.76 | -79.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PYXS forecast.
Our base-case forecast reaches $5.30 around 2030.
Implied market cap at $5.30: $335.78M
The multi-year forecast shows a clear long-run upside path. In 2026 the avg price is $2.65 with a min of $1.15 and a max of $4.00, and a 0% ROI, with NEUTRAL sentiment. The outlook strengthens into 2027 with an avg of $3.10 and 16.8% ROI, and by 2028 the avg rises to $3.72 with 40.3% ROI.
The pivotal milestones appear in 2030, where the avg is $7.11 and the max is $12.31, yielding a 168.1% ROI and a BULLISH stance. The trajectory continues to 2040 (avg $20.46, max $44.86, ROI 672%) and 2050 (avg $67.22, max $154.61, ROI 2436.6%), both labeled BULLISH.
These figures reflect broad upside potential tied to Pyxis Oncology’s clinical-stage pipeline, including PYX-201, PYX-102, PYX-106, PYX-107, and licensing arrangements with Pfizer and Biosion USA. They are estimates, not guarantees, and depend on clinical outcomes, regulatory decisions, and market dynamics.
Tap a question to reveal the answer.
According to the forecast, PYXS has an avg price of $7.11 in 2030 with a min of $4.40 and a max of $12.31; the ROI is 168.1% and the sentiment is BULLISH.
The 2026 forecast is NEUTRAL with an avg of $2.65 and ROI of 0%, but the outlook improves in later years, with 2030 (avg $7.11, ROI 168.1%), 2040 (avg $20.46, ROI 672%), and 2050 (avg $67.22, ROI 2436.6%) showing bullish potential. These are estimates, not guarantees.
Yes. The 2050 max forecast is $154.61, which exceeds $50, indicating a potential to surpass that level in the max scenario.
The current price is $2.65 and the market cap is $167.89M.
The 30-day range is $1.77 to $3.97, RSI(14) is 50, SMA50 is $2.24, SMA200 is $2.34, with support at $2.03 and resistance at $3.07. The sentiment is BULLISH.
Pyxis Oncology, Inc. Community Discussion
0Share your Pyxis Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.